Yso 3
Alternative Names: Yso-3Latest Information Update: 28 Feb 2025
At a glance
- Originator YSOPIA Bioscience
- Developer National Institute for Agricultural Research; YSOPIA Bioscience
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Inflammatory-bowel-diseases in France
- 27 Jan 2021 Early research in Inflammatory bowel diseases in France (unspecified route)
- 27 Jan 2021 YSOPIA bioscience announces intention to file IND application for Inflammatory bowel diseases by the end of 2021 (YSOPIA bioscience pipeline, January 2021)